A lower quality of life for children
Globally, more than 300,000 children suffer from JIA and it is the most common chronic rheumatologic disease. JIA is a heterogeneous group of disorders with clinical manifestation of chronic joint inflammation. With existing therapy, some children recover and live normal lives, while children with severe cases of JIA continue to suffer from poor growth, progressive joint destruction and/or systemic inflammatory disease, disability, and poor quality of life.
When taking into account patients from all JIA subtypes, patients suffering from systemic-onset JIA in particular, face a poor prognosis- independent of treatment. There is no unique JIA treatment, instead current treatment strategies are mostly adopted from rheumatoid arthritis (RA) treatments for adults.
The researchers at Lipum have identified a novel target molecule that plays an important role in the development of chronic inflammations. By selective inhibition of the target, the inflammation shall be eliminated with less adverse effects than today’s treatments.
The mission is to develop a new, unique biologic pharmaceutical for treatment of JIA and other chronic inflammatory diseases, based on the discovery that the protein bile salt-stimulated lipase (BSSL) is a key molecule in the mechanism. This discovery stems from extensive pre-clinical studies in well-established arthritis models.
The team has leading expertise and is well known within the international scientific community for BSSL research. Moreover, extensive experience from clinical medicine and the pharmaceutical industry in combination with a strong IP portfolio with granted patents constitutes a solid foundation for success.
Below: The CEO of Lipum presents at Biostock Live streamed online in August 2018.